

Mutated in Colorectal Cancer Protein Modulates the NFκB Pathway

NICHOLAS D. SIGGLEKOW¹, LAURENT PANGON¹, TILMAN BRUMMER^{1,2,3},
MARK MOLLOY⁴, NICHOLAS J. HAWKINS⁵, ROBYN L. WARD⁵,
ELIZABETH A. MUSGROVE^{1,6} and MAIJA R. J. KOHONEN-CORISH^{1,6}

¹Cancer Research Program, Garvan Institute of Medical Research, Sydney, Australia;

²Centre for Biological Systems Analysis (ZBSA), Centre for Biological Signalling Studies BIOSS and

³Institute for Biology III, Albert Ludwig University, Freiburg, Germany;

⁴Australian Proteome Analysis Facility, Department of Chemistry and
Biomolecular Sciences, Macquarie University, Sydney, Australia;

⁵Prince of Wales Clinical School and Lowy Cancer Research Centre, UNSW, Sydney, Australia;

⁶St. Vincent's Clinical School, Faculty of Medicine, UNSW, Sydney, Australia

Abstract. *Background: The tumour suppressor gene 'mutated in colorectal cancer' (MCC) is silenced through promoter methylation in colorectal cancer and has been implicated as a regulator of the nuclear factor kappa B (NFκB) pathway. Therefore, we aimed to determine whether MCC modulates NFκB activation in colorectal cancer. Materials and Methods: NFκB activation was assessed using luciferase reporter assays in colorectal cancer cells in vitro. MCC methylation was analysed in primary tumour specimens from patients with inflammatory bowel disease. Results: Re-expression of MCC reduced NFκB-dependent transcription in tumour necrosis factor alpha (TNFα)- or lipopolysaccharide (LPS)-stimulated cells. Conversely, knockdown of MCC resulted in accumulation of the inhibitor of kappa B alpha (IKBα) protein, encoded by NFKBIA, a first response gene specifically and rapidly regulated by NFκB pathway activation. The MCC gene is methylated in up to 6/16 of inflammatory bowel disease-associated tissue specimens, and myosin-10 and valosin-containing protein were identified as MCC-interacting proteins. Conclusion: These findings suggest that MCC modulates NFκB pathway signalling indirectly in colorectal cancer cells.*

The MCC gene was discovered during the search for the familial adenomatous polyposis locus because of its close linkage to the APC gene (1). However, as MCC is only rarely mutated in colorectal cancer (CRC) (2), its significance in carcinogenesis was initially poorly understood. It was recently reported that the MCC gene promoter is methylated in up to 50% of CRCs and 80% serrated polyps, suggesting that its silencing is important in early colon carcinogenesis via the serrated neoplasia pathway (3, 4). Furthermore, an unbiased genetic screening of a mouse model of CRC implicated MCC mutation as a key event in colorectal carcinogenesis (5), providing evidence that it is a tumour suppressor gene. These findings have renewed interest in the cellular function of MCC.

MCC has been implicated as a negative regulator of the cell cycle and cell proliferation (6). We have confirmed the role of MCC in cell cycle regulation in CRC cells and shown that MCC protein phosphorylation is required in response to DNA damage caused by single-strand DNA breaks (7). MCC has also been implicated as a modulator of the nuclear factor kappa B (NFκB) signalling pathway through its interaction with the inhibitor of kappa B (IKB), the cytoplasmic inhibitor of NFκB signalling (8). However, the functional significance of this interaction in CRC was not addressed in this large-scale mapping study of NFκB–protein interactions. Thus, the potential interplay between MCC and NFκB signalling has yet to be determined, in particular in CRC, where MCC is frequently silenced by promoter methylation.

The NFκB signalling pathway is important in the normal development of the colorectum and maintenance of colonocyte viability, but is aberrantly activated in CRC (9–11). Patients with inflammatory conditions, such as ulcerative colitis, exhibit increased NFκB activity in

Correspondence to: Maija Kohonen-Corish, Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Sydney NSW 2010, Australia. Tel: +61 292958336, Fax: +61 292958321, e-mail: m.corish@garvan.org.au

Key Words: Colorectal cancer, inflammatory bowel disease, NFκB pathway, TNFα.

colonocytes and have a greater risk of developing CRC (12). NF κ B activation in both epithelial and myeloid cells contributes to CRC and this has been described as an important link between inflammation and cancer (13, 14).

Numerous NF κ B activators have been described, including a diverse array of ligand–receptor interactions. Rapid canonical NF κ B signalling by inflammatory factors is mediated mainly by members of the interleukin and tumour necrosis factor receptor (TNFR) protein superfamilies, the best characterized being TNFR1 (15, 16). Transduction of the initiating signal, such as TNF α or lipopolysaccharide (LPS), is mediated by intracellular proteins, which induce a signalling cascade culminating in activation of the I κ B kinases (IKK), IKK α or IKK β . These kinases phosphorylate NF κ B cytoplasmic inhibitors I κ B α and I κ B β , leading to the nuclear translocation and activation of NF κ B transcription factors RelA or RelB.

Therefore, due to the strong association between increased NF κ B activity and the predisposition to CRC, the high frequency of *MCC* methylation in early colorectal polyps, and the reported interaction between *MCC* and I κ B β , the effect of *MCC* expression on NF κ B signalling was further examined.

Materials and Methods

Patient cohort and MCC methylation analysis. Colorectal carcinoma specimens from individuals with inflammatory bowel disease were drawn from patients who had undergone complete surgical resection of a primary CRC between 1993-2010. The 16 individuals (9 male and 7 female) were aged 31 to 82 years. Genomic DNA was extracted from cancer and the matching non-cancer colonic mucosa. Quantitative real-time PCR for *MCC* gene promoter methylation was carried out using an ABI7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA) and *myogenic differentiation 1 (MYOD)* as the reference gene as previously described (3, 17).

Construction of plasmids. Full-length *MCC* cDNA (2490 bp) was amplified by PCR from cDNA clone MGC:12731 (Invitrogen, Carlsbad, CA, USA) using extended attB primers (forward 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGAATCCG GAGTTGC-3'; reverse 5'-GGGGACCACTTTGTACAAGAAAGCT GGGTATTAAGCGAAGTTTCATT-3') and cloned into the Gateway entry vector pDONR221 (Invitrogen). Wild-type *MCC* was subsequently recombined into pcDNA3.1/nV5-DEST (Invitrogen) using the Gateway[®] LR reaction as per the manufacturer's instructions.

Protein analysis. Cell lysates were generated using RIPA buffer supplemented with protease inhibitors (3), and proteins (10-30 mg) were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 8% acrylamide gels. The following antibodies were used for Western blot analysis: from Cell Signaling Technology (Danvers, MA, USA) AKT (#9272), phospho-AKT (#9271), ERK1/2 (#4696), phospho-ERK1/2 (E10, #9106), I κ B α (#9242), phospho-I κ B α (#14D4, #2859), I κ B β (#9248), phospho-I κ B β (#4821), IKK β (#2684), phospho-IKK α / β (16A6,

#2697), RelA (#3034), phospho-RelA (93H1, #3033), as well as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (4300; Ambion, Austin, TX, USA), myosin-10 (M7937; Sigma, St Louis, MO, USA), nV5 (46-0705; Invitrogen), VCP (sc-20799; Santa Cruz Biotechnology, Santa Cruz, CA, USA), and *MCC* (610740; BD Transduction Laboratories[™], Franklin Lakes, NJ, USA).

Mass spectrometry (NanoLC ESI MS MS) was performed using Agilent 1100 Series (Agilent Technologies, Boeblingen, Germany) and QStar XL (Applied Biosystems, Framingham, MA, USA) instruments. Peptides were assigned by searching the SWISS-PROT human protein database using Mascot (Matrix Sciences, London, UK). *MCC*-binding partners were confirmed by standard immunoprecipitation (IP) method using the Tris, Sodium Chloride, EDTA (TNE) buffer system, followed by Western blot.

Luciferase activity assays. KM12SM and HCT-15 (CCL-225[™]; American Type Culture Collection, ATCC, Manassas, VA, USA) cells were transfected in triplicate with a NF κ B-luciferase reporter (0.66 μ g) (18), a *lacZ*/beta-galactosidase expression plasmid to control for transfection efficiency (0.33 μ g; pEF/GW-51/*lacZ*; Invitrogen) and either 1.5 μ g of empty pcDNA3.1/nV5-DEST or the *MCC*-containing equivalent vector. Transfection medium was replaced with serum starvation (SS) medium (0.2% fetal calf serum, FCS) 24 h post-transfection, and the cells serum-starved for a further 16 h. To determine changes in NF κ B activation, cells were stimulated with either TNF α (10 ng/ml, Cytolab, Rehovot, Israel) or LPS (10 μ g/ml, Invivogen, San Diego, CA, USA) for 6 h. Lysates were harvested and NF κ B-luciferase and β -galactosidase activity was determined using the Galacto-Star[™] System (Tropix Inc, Bedford, MA, USA). Relative luciferase activity for a sample was determined by dividing the average NF κ B-luciferase activity, by the relative amount of β -galactosidase activity.

Treatment with siRNAs. SW480 (CCL-228[™]; ATCC) and HEK293 (CRL-1573[™]; ATCC) cells were transfected using Lipofectamine2000 with 10 nM ON-TARGET^{plus} siRNA from Dharmacon (Lafayette, CO, USA): *MCC* siRNA #9 (J-010523-09), *MCC* siRNA #10 (J-010523-10), non-targeting #2 control siRNA (D-001810-02-20) and RNA-induced silencing complex (RISC)-free control siRNA (D-001220-01-20), as per the manufacturer's instructions. Opti-mem (31985, GIBCO[®]; Invitrogen) was used in place of serum-free media. siRNA concentration of 10 nM resulted in a reduction of *MCC* expression between 80-90% compared to controls.

Caspase-8 activation and global apoptosis assays. HCT-15 cells were transfected with 1.5 μ g empty vector, or wild-type *MCC*-expressing construct. Twenty-four hours post-transfection, cells were cultured in SS medium for 16 h, followed by stimulation with TNF α (10 ng/ml in 5% FCS medium) for 24 h. Caspase-8 activation was assayed from floating and adherent cells (Apoptosis Detection Kit – Caspase-8; Kamiya Biomedical Company, Seattle, WA, USA) and the covalently-bound fluorescent caspase-8 inhibitor was detected using the FL-1 channel by flow cytometry. Caspase-8 activation was determined by comparisons of the number of fluorescent cells before and after TNF α treatment. To determine global apoptosis, floating and adherent cells were collected from empty vector or *MCC*-expressing HCT-15 cells were subjected to the same TNF α treatment used for luciferase assays, and the DNA content determined by staining with propidium iodide and analysis by flow cytometry.




Figure 1. *MCC* modulates NFκB-mediated transcription. KM12SM cells (A, B) and HCT-15 cells (C) were transfected in triplicate with the NFκB reporter, a lacZ transfection control plasmid, and either *MCC.pcDNA3.1/nV5-DEST* or empty vector control for 24 h. Cells were cultured in serum starvation (SS) medium (0.2% FCS), or SS medium supplemented with TNFα (10 ng/ml) or LPS (10 μg/ml) for 6 h prior to harvesting (A, B) or harvested hourly at 1-6 h (C).

Statistical analysis. Paired *t*-tests were used to determine the level of significance between experimental groups (Excel). *P*-values for differences between fold-change across three separate luciferase experiments were generated by performing a two-sided paired *t*-test, assuming equal variance as indicated by the data after log transformation.

Results

MCC gene is methylated in a subset of inflammatory bowel disease-associated tissue specimens. In order to investigate a possible role of the *MCC* defect in inflammation-associated CRC, we first analyzed a series of primary tumours resected from inflammatory bowel disease patients. *MCC* methylation was detected in 6/16 of the tumours and in 3/16 of the matching non-cancer tissue specimens. In one patient, both specimens showed *MCC* methylation, but in the others, methylation was only found in either the cancer or the matching non-cancer tissue from the inflamed colon. In contrast, *MCC* methylation was not observed in the normal colon of healthy controls (3).

MCC modulates NFκB transcriptional activity in colorectal cancer cells. The effect of *MCC* re-expression on NFκB-dependent transcription was investigated in serum starved KM12SM cells in which *MCC* expression is abolished due to methylation of the promoter (3). Pathway-dependent transcription was measured by luciferase activity after co-transfection of *MCC* or control vectors and a NFκB luciferase reporter in conditions where the NFκB pathway is activated. Transient *MCC* expression consistently reduced the magnitude of NFκB activation in response to both TNFα and LPS in three separate experiments (Figure 1A and B;




Figure 2. *MCC* overexpression reduces levels of key NFκB signalling proteins. KM12SM cells were transfected with *MCC* or an empty vector control for 24 h. Cells were cultured for a further 16 h in full medium or SS medium, followed by a 6 h incubation in full, SS, or SS media supplemented with TNFα (10 ng/ml) or LPS (10 μg/ml). Proteins (20 μg) were separated by SDS-PAGE and subjected to western blot. Primary antibodies were incubated overnight, and protein levels visualized by chemiluminescence. GAPDH was used as the protein loading control.




Figure 3. *MCC* knockdown increases *IκBα* levels on *TNFα* stimulation. HEK293 cells were transfected with 10 nM *MCC*-specific siRNAs (siRNA #9 and siRNA #10), or control siRNAs (RISC-free and Non-targeting #2) for 24 h, followed by culture in SS medium for 16 h. Cells were stimulated with *TNFα* (10 ng/ml) and protein lysates collected at the time points indicated. Proteins were separated by SDS-PAGE and subjected to Western blot. GAPDH was used as the protein loading control.

$p=0.0003$ and $p=0.0127$, respectively). Similar results were obtained for a second *MCC*-null CRC cell line, HCT-15. A time-course experiment showed that the inhibitory effect of *MCC* re-expression was detectable after 3 h of *TNFα* treatment (Figure 1C).

MCC re-expression decreases the levels of *NFκB* pathway proteins. Because *MCC* re-expression reduced *NFκB* transcriptional activity in response to both *TNFα* and LPS, the protein levels of major *NFκB* pathway signalling proteins were examined. *MCC* re-expression in KM12SM cells caused a 40-50% decrease in the total and phosphorylated protein levels of the *NFκB* pathway components RelA, *IκBα* and *IκBβ* after 6 h of *TNFα*, and after LPS treatment (Figure 2). In serum-starved cells, there was a similar small decrease of phosphorylated, as well as total RelA, *IκBα* and *IκBβ* with *MCC* re-expression. Down-regulation of total protein levels was specific for *NFκB* signalling proteins, as AKT (PI3K signalling), and both ERK1 and ERK2 (MAPK signalling pathway) protein levels remained relatively unchanged (Figure 2). Conversely, knockdown of *MCC* levels in HEK293 cells resulted in an accumulation of *IκBα* protein (Figure 3), encoded by *NFκBIA*, a first response gene specifically and rapidly transcribed by *NFκB* (19). When stimulated with *TNFα* for 60 min, coincident RelA phosphorylation and degradation of accumulated *IκBα* was observed in HEK293 cells with normal *MCC* expression (Figure 3). With *MCC* knockdown, RelA phosphorylation was unchanged in response to *TNFα* stimulation, but there was a delay in *IκBα* protein degradation, indicating increased *IκBα* transcription and *NFκB* activity.

MCC re-expression does not increase global apoptosis. Because a reduction in *NFκB* signalling can result in increased apoptosis, we tested whether *MCC*-induced *NFκB* inhibition could affect the number of cells undergoing *TNFR1*-mediated apoptosis. The number of cells with activated caspase-8, an essential initiator of *TNFR1*-associated apoptosis, increased in the presence of *TNFα*, indicating a functional *TNFR1*-mediated apoptosis pathway in this cell line. However, *MCC* re-expression did not further increase *TNFα*-mediated apoptosis compared to vector-transfected control cells (24.2% vs. 30.9% of *TNFα* treated cells; Figure 4A and B), thus the presence of *MCC* did not promote a pro-apoptotic response during chronic *TNFα* stimulation. Furthermore, an increase in the number of cells exhibiting DNA fragmentation, a marker of global apoptosis, was not observed in *MCC*-overexpressing cells compared with controls in both unstimulated (12.1% vs. 11.8%; Figure 4C and D) and *TNFα* treated cells (15.4% vs. 15.8%; Figure 4E and F).

MCC interacts with myosin-10 and valosin-containing protein. To gain further insight into how *MCC* may exert its suppressive effect on *NFκB* signalling, proteins that co-immunoprecipitated with endogenous *MCC* from HEK293 were identified by mass spectrometry (Table I). We did not observe the previously reported *MCC* interaction with *IκBβ* (8) but identified myosin-10 (MYH10), which was previously detected in a large-scale study of protein-protein interactions as an *MCC*-binding partner (20). In additional mass spectrometry experiments, FLAG-tagged *MCC* was immunoprecipitated with a FLAG antibody from SW480 colorectal cancer cells (7). This detected another *MCC*-




Figure 4. Re-expression of MCC does not promote apoptosis. Cells with activated caspase-8 were detected and counted by flow cytometry using the FL1-H channel. The empty curves represent histogram counts from unstimulated HCT-15 cells, shaded curves for TNF α -treated cells, and percentages shown are the proportion of the population contained within the active caspase-8 gate of control (A), and MCC-expressing cells (B). Global apoptosis was determined flow cytometry by identification of the sub-G₁ DNA content population (%) in MCC (D, F) and control (C, E) transfected cells. Transfected cells were subjected to culture in SS medium (C, D) and SS medium supplemented with TNF α (10 ng/ml; E, F) for 6 h.

interacting protein that was found in the large-scale study, valosin-containing protein (VCP). Subsequently, we confirmed the interaction of MCC with MYH10 and VCP in KM12SM colorectal cancer cells overexpressing MCC using co-immunoprecipitation (Figure 5) but again, an interaction with I κ B β was not detected.

Discussion

MCC is emerging as a multifunctional protein that affects several cellular processes and pathways, such as NF κ B (8), Wnt signalling (4) and the cell cycle (6, 7). Re-expression of MCC inhibits cell proliferation in several cancer cell lines




Figure 5. Confirmation of the MCC protein interaction with the MYH10 and VCP proteins. KM12SM cells were transfected with MCC or control vectors for 8 h, and cultured in media containing 10% serum for a further 40 h. Lysates were generated using TNE/0.5%Triton-x100, and immunoprecipitates were generated from total protein (10 mg) by incubation for 2 h with 2 μ g antibody and isolation using protein-G-sepharose 2B beads. Entire samples were loaded, and proteins separated by SDS-PAGE and subjected to Western blot analysis.

Table I. The highest ranking proteins that immunoprecipitated with the MCC antibody in HEK293 cells, detected with mass spectrometry. Candidate MCC-interacting proteins, which were not detected in negative controls, are shown in bold.

Rank order	Protein name	UniProt accession ID	Mascot Score	Detected in controls [†]
1	Myosin-9	P35579	1266	Y
2	Myosin-10, MYH10	P35580	379	N
3	Actin, cytoplasmic 1	P60709	313	Y
4	Annexin A1	P04083	225	S
5	MCC	P23508	214	N
6	Actin aortic smooth muscle	P62736	206	Y
7	HSP 70 kDa protein 1	P08107	199	Y
8	Peroxiredoxin-1, PRDX1	Q06830	171	N
9	Histone H1.2	P16403	153	Y
10	Tubulin alpha-1A chain	Q71U36	141	N
11	Tubulin beta-2A chain	Q13885	139	N
12	Myosin light peptide 6	P60660	114	Y
13	HS cognate 71kDa protein	P11142	114	Y

[†]Negative controls: Immunoprecipitates from MCC-null HCT-15 cells (MCC antibody) and HEK293 cells (matched IgG isotype antibody). N: Protein was not identified in negative controls; Y: protein was identified in negative controls; S: similar protein was identified in controls.

(4, 6, 7). However, it is poorly understood how the loss of MCC promotes carcinogenesis in the colon.

MCC gene is silenced through promoter methylation in CRC and in precancerous polyps (3, 4). The reported frequency of MCC methylation in sporadic CRC is 40-50%.

To date, *MCC* methylation has not been described in any other type of cancer. Here we show for the first time that the *MCC* gene is methylated in 6/16 of inflammatory bowel disease-associated cancers and 3/16 of the adjacent control tissues. It is possible that the flat tissue in the inflamed colon of these patients contains dysplastic regions, which may explain the presence of *MCC* methylation in the matching non-cancer specimens. We have previously observed *MCC* methylation in premalignant sporadic polyps, but not in the normal colon.

NF κ B activation is central to the neoplastic transformation of epithelial cells in the context of chronic colon inflammation (13, 14). Therefore, loss of factors that normally inhibit NF κ B signalling may contribute to the disease progression or carcinogenesis in chronic inflammatory bowel disease. This study describes a new role for *MCC* as a transcriptional modulator of the NF κ B pathway in CRC cells, which was previously suggested in HEK293 human embryonic kidney cells (8). While re-expression of *MCC* reduced activation of NF κ B signalling in response to TNF α and LPS, it did not result in increased caspase activity or apoptosis in CRC cells despite specific reduction in key NF κ B pathway signalling protein levels. An increase in I κ B α was observed on *MCC* knockdown with siRNA, which suggests that *MCC* depletion increased NF κ B pathway activity, as *NFKBIA* is a gene rapidly induced by NF κ B activity due to three NF κ B response elements present in the promoter region (19). *NFKBIA* plays a self-limiting and critical role in the negative feedback NF κ B pathway signalling.

MCC has previously been found in complex with I κ B β , which together with I κ B α , binds to RelA preventing its translocation to the nucleus and transcription of NF κ B target genes (8). While *MCC* binding to I κ B β would potentially explain how *MCC* modulates the NF κ B pathway (8), we could not confirm this interaction. However, we identified other binding partners for *MCC* in IP mass spectrometry experiments, including other possible regulators of NF κ B signalling. There were similarities between the *MCC*-interacting proteins identified in this study and a previous study by Ewing *et al.* (20), which used *MCC* as a 'bait' protein. Two proteins, MYH10 and VCP, were identified in both studies suggesting a robust interaction. These interactions were confirmed here by co-IP in CRC cells. Ewing *et al.* placed MYH10 and VCP in the top ten most robust *MCC* interactions as determined by the interaction confidence scores (20). Both VCP and MYH10 have been implicated in NF κ B signalling through multiple protein-protein interactions. VCP interacts with I κ B α , I κ B β and I κ B ϵ , MYH10 with RelA, IKK β and NEMO and both proteins interact with IKK ϵ (8, 20).

Apart from large-scale protein-protein interaction studies, there is some evidence for functional interactions of MYH10 and VCP with NF κ B signalling. MYH10 is a structural part of the active cytoskeleton, which is rearranged during TNF α -

induced RelA nuclear translocation (21). VCP can affect NF κ B activation directly through binding to cytoplasmic I κ B α causing its degradation, which is required for the nuclear translocation of NF κ B transcription factors (22). It has been suggested that this provides a cellular mechanism whereby aberrant VCP activity promotes tumour metastasis in an experimental osteosarcoma model (23). In colorectal carcinoma, high expression of VCP is associated with poor prognosis and disease recurrence (24).

MCC is emerging as a multifunctional protein that can affect the transcription of multiple pathways including Wnt and NF κ B. The functional diversity of *MCC* binding partners suggests that *MCC* may have diverse roles in the colon. Mutated *MCC* has been shown to be a driver of carcinogenesis in a mouse model of CRC (5), indicating that an *MCC* defect is functionally important in early lesions (3). *MCC* silencing may also be important in a subset of inflammation-associated CRC.

Acknowledgements

The Authors thank the Cancer Institute NSW, Cancer Council NSW and the Australian Cancer Research Foundation for funding, Nicola Currey and Allison Arndt for technical assistance. MKC and EAM are Cancer Institute NSW Career Development Fellows and NDS is a recipient of the University of NSW Postgraduate Award.

References

- 1 Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hamilton SR, Hedge P, Markham A, Carlson M, Joslyn G, Groden J, White R, Miki Y, Miyoshi Y, Nishisho I and Nakamura Y: Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. *Science* 251: 1366-1370, 1991.
- 2 Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S and Hedge P: Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. *Science* 253: 665-669, 1991.
- 3 Kohonen-Corish MRJ, Sigglekow ND, Susanto J, Chapuis PH, Bokey EL, Dent OF, Chan C, Lin BPC, Seng TJ, Laird PW, Young J, Leggett BA, Jass JR and Sutherland RL: Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. *Oncogene* 26: 4435-4441, 2007.
- 4 Fukuyama R, Nicolaita R, Ng KP, Obusez E, Sanchez J, Kalady M, Aung PP, Casey G and Sizemore N: Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses β -catenin-dependent transcription. *Oncogene* 27: 6044-6055, 2008.
- 5 Starr TK, Allaei R, Silverstein KAT, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O'Sullivan MG, Matise I, Dupuy AJ, Collier LS, Powers S, Oberg AL, Asmann YW, Thibodeau SN, Tessarollo L, Copeland NG, Jenkins NA, Cormier RT and Largaespada DA: A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. *Science* 323: 1747-1750, 2009.

- 6 Matsumine A, Senda T, Baeg G-H, Roy BC, Nakamura Y, Noda M, Toyoshima K and Akiyama T: MCC, a cytoplasmic protein that blocks cell cycle progression from the G₀/G₁ to S phase. *J Biol Chem* 271: 10341-10346, 1996.
- 7 Pangon L, Siggelkow ND, Larance M, Al-Sohaily S, Mladenova D, Selinger C, Musgrove EA and Kohonen-Corish MRJ: 'Mutated in colorectal cancer' (MCC) is a novel target of the UV-induced DNA damage response. *Genes Cancer* 1: 917-926, 2010.
- 8 Bouwmeester T, Bauch A, Ruffner H, Angrand P-O, Bergamini G, Coughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C, Huhse B, Mangrano R, Michon A-M, Schirle M, Schlegl J, Schwab M, Stein M, Bauer A, Casari G, Drewes G, Gavin A-C, Jackson D, Joberty G, Neubauer G, Rick J, Kuster B and Superti-Furga G: A physical and functional map of the human TNFα/NFκB signal transduction pathway. *Nature Cell Biol* 6: 97-105, 2004.
- 9 Wang S, Liu Z, Wang L and Zhang X: NFκB signalling pathway, inflammation and colorectal cancer. *Cell Mol Immunol* 6: 327-324, 2009.
- 10 Lind DS, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G, Moldawer LL, Copeland EM and MacKay S: Nuclear factor-κB is up-regulated in colorectal cancer. *Surgery* 130: 363-369, 2001.
- 11 Yu H-G, Yu L-L, Yang Y, Luo H-S, Yu J-P, Meier JJ, Schrader H, Bastian A, Schmidt WE and Schmitz F: Increased expression of RelA/NFκB protein correlates with colorectal tumorigenesis. *Oncology* 65: 37-45, 2003.
- 12 Seril DN, Liao J, Yang G-Y and Yang CS: Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. *Carcinogenesis* 24: 353-362, 2003.
- 13 Greten FR, Eckmann L, Greten TF, Park JM, Li Z-W, Egan LJ, Kagnoff MF and Karin M: IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell* 118: 285-296, 2004.
- 14 Karin M and Greten FR: NFκB: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol* 5: 749-759, 2005.
- 15 Chen G and Goeddel DV: TNF-R1 signaling: A beautiful pathway. *Science* 296: 1634-1635, 2002.
- 16 Hayden MS and Ghosh S: Signaling to NFκB. *Genes Dev* 18: 2195-2224, 2004.
- 17 Seng TJ, Currey N, Cooper WA, Lee CS, Chan C, Horvath L, Sutherland RL, Kennedy C, McCaughan B and Kohonen-Corish MRJ: *DLEC1* and *MLH1* promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. *Br J Cancer* 99: 375-82, 2008.
- 18 Minguet S, Huber M, Rosenkranz L, Schamel W, Reth M and Brummer T: Adenosine and cAMP are potent inhibitors of the NFκB pathway downstream of immunoreceptors. *Eur J Immunol* 35: 31-41, 2005.
- 19 Hoffmann A, Levchenko A, Scott ML and Baltimore D: The IκB-NFκB signaling module: temporal control and selective gene activation. *Science* 298: 1241-1245, 2002.
- 20 Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L, Robinson MD, O'Connor L, Li M, Taylor R, Dharsee M, Ho Y, Heilbut A, Moore L, Zhang S, Ornatsky O, Bukhman YV, Ethier M, Sheng Y, Vasilescu J, Abu-Farha M, Lambert J-P, Duetzel HS, Stewart II, Kuehl B, Hogue K, Colwill K, Gladwish K, Muskat B, Kinach R, Adams S-L, Moran MF, Morin GB, Topaloglou T and Figeys D: Large-scale mapping of human protein-protein interactions by mass spectrometry. *Mol Systems Biol* 3: 1-17, 2007.
- 21 Wadgaonkar R, Linz-McGillem L, Zaiman AL and Garcia JG: Endothelial cell myosin light chain kinase (MLCK) regulates TNFα-induced NFκB activity. *J Cell Biochem* 94: 351-64, 2005.
- 22 Dai R-M, Chen E, Longo DL, Gorbea CM and Li C-CH: Involvement of valosin-containing protein, an ATPase co-purified with IκBα and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IκBα. *J Biol Chem* 273: 3562-3573, 1998.
- 23 Asai T, Tomita Y, Nakatsuka S, Hoshida Y, Myoui A, Yoshikawa H and Aozasa K: VCP (p97) regulates NFκB signaling pathway, which is important for metastasis of osteosarcoma cell line. *Jpn J Cancer Res* 93: 296-304, 2002.
- 24 Yamamoto S, Tomita Y, Hoshida Y, Sakon M, Kameyama M, Imaoka S, Sekimoto M, Nakamori S, Monden M and Aozasa K: Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. *Clin Cancer Res* 10: 651-657, 2004.

Received October 5, 2011
Revised December 1, 2011
Accepted December 2, 2011